Detalhe da pesquisa
1.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood;
140(2): 112-120, 2022 07 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35427411
2.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood;
138(26): 2810-2827, 2021 12 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34407545
3.
Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia.
Clin Infect Dis;
74(9): 1659-1668, 2022 05 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33870413
4.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med;
381(5): 432-443, 2019 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31365801
5.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet;
395(10232): 1278-1291, 2020 04 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32305093
6.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med;
379(26): 2517-2528, 2018 12 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30501481
7.
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Blood;
134(2): 111-122, 2019 07 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31023700
8.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood;
133(19): 2031-2042, 2019 05 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30842083
9.
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
Blood;
131(25): 2782-2788, 2018 06 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29618479
10.
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
Blood;
131(21): 2331-2334, 2018 05 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29487070
11.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Blood;
131(13): 1415-1424, 2018 03 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29348128
12.
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Blood;
131(17): 1910-1919, 2018 04 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29437592
13.
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Blood;
131(15): 1704-1711, 2018 04 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29305552
14.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Br J Haematol;
184(4): 558-569, 2019 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30506764
15.
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
Blood;
129(13): 1763-1767, 2017 Mar 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28082441
16.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood;
129(19): 2612-2615, 2017 05 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28373262
17.
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Haematologica;
104(11): 2258-2264, 2019 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30923097
18.
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.
J Natl Compr Canc Netw;
17(5): 414-423, 2019 05 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31085755
19.
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw;
17(6): 721-749, 2019 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31200351
20.
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Am J Hematol;
94(5): 554-562, 2019 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30767298